Key facts
- Arrowsmith’s last known valuation is $4.3M (Jul 2025).
- It has raised $2.1M; the latest was Seed Round ($2.1M) in Jul 2025.
- Notable investors include JIC Venture Growth Investments, Jafco.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Arrowsmith
- ·The full record, as it builds
Funding rounds
No funding rounds for Arrowsmith are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arrowsmith
Operator of a drug discovery firm intended to develop phage therapy for drug-resistant bacterial infections. The company utilizes bacteriophages, which are viruses that prey on bacteria, enabling patients suffering from antibiotic-resistant infections to access treatments that are difficult to treat using traditional medicines.
- Sector
- Healthcare
- HQ
- Tsukuba, Japan
- Founded
- 2025
- Employees
- 3
- Website
- arrowsmith.co.jp/
- Ownership
- Privately Held (backing)
Arrowsmith doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arrowsmith shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arrowsmith in its N-PORT filings yet. We sweep new filings monthly.